Jinlan Luo

519 total citations
29 papers, 368 citations indexed

About

Jinlan Luo is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Biochemistry. According to data from OpenAlex, Jinlan Luo has authored 29 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 7 papers in Biochemistry. Recurrent topics in Jinlan Luo's work include Eicosanoids and Hypertension Pharmacology (6 papers), Diet, Metabolism, and Disease (4 papers) and Diabetes Treatment and Management (3 papers). Jinlan Luo is often cited by papers focused on Eicosanoids and Hypertension Pharmacology (6 papers), Diet, Metabolism, and Disease (4 papers) and Diabetes Treatment and Management (3 papers). Jinlan Luo collaborates with scholars based in China, United States and Poland. Jinlan Luo's co-authors include Ling Tu, Xizhen Xu, Menglu Fu, Ruolan Dong, Shuiqing Hu, Yan Yang, Wenhua Li, Zhihui Chen, Jing Yu and Lili Shi and has published in prestigious journals such as Journal of Biological Chemistry, International Journal of Molecular Sciences and Cellular and Molecular Life Sciences.

In The Last Decade

Jinlan Luo

26 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jinlan Luo China 11 127 59 50 50 47 29 368
Menglu Fu China 11 127 1.0× 64 1.1× 45 0.9× 48 1.0× 47 1.0× 16 342
Yanjun Zhong China 15 173 1.4× 40 0.7× 55 1.1× 45 0.9× 56 1.2× 35 609
Afagh Garjani Iran 13 172 1.4× 35 0.6× 30 0.6× 76 1.5× 51 1.1× 42 517
Stanislav Kotlyarov Russia 14 167 1.3× 29 0.5× 36 0.7× 49 1.0× 29 0.6× 50 491
Ping Lv China 13 195 1.5× 20 0.3× 32 0.6× 89 1.8× 58 1.2× 24 512
Francesco Palmas Italy 14 174 1.4× 26 0.4× 15 0.3× 43 0.9× 20 0.4× 23 509
Elisabet Rodríguez‐Tomàs Spain 13 167 1.3× 27 0.5× 28 0.6× 37 0.7× 28 0.6× 26 381
Chengxia Kan China 13 193 1.5× 99 1.7× 51 1.0× 85 1.7× 35 0.7× 46 518
Weifeng Yao China 12 122 1.0× 53 0.9× 27 0.5× 48 1.0× 8 0.2× 28 382

Countries citing papers authored by Jinlan Luo

Since Specialization
Citations

This map shows the geographic impact of Jinlan Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinlan Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinlan Luo more than expected).

Fields of papers citing papers by Jinlan Luo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinlan Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinlan Luo. The network helps show where Jinlan Luo may publish in the future.

Co-authorship network of co-authors of Jinlan Luo

This figure shows the co-authorship network connecting the top 25 collaborators of Jinlan Luo. A scholar is included among the top collaborators of Jinlan Luo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinlan Luo. Jinlan Luo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Shuiqing, Jingrui Liu, Jinlan Luo, et al.. (2025). Diabetic vascular calcification inhibited by soluble epoxide hydrolase gene deletion via regressing NID2-mediated IGF2-ERK1/2 signaling pathway. Chinese Medical Journal. 138(20). 2657–2668.
2.
3.
Sun, Hongtao, et al.. (2025). Enhancing HVAC Control Systems Using a Steady Soft Actor–Critic Deep Reinforcement Learning Approach. Buildings. 15(4). 644–644. 4 indexed citations
4.
5.
Chen, Yunling, et al.. (2024). Construction of a pH- and viscosity-switchable near-infrared fluorescent probe and its imaging application. Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy. 319. 124527–124527. 4 indexed citations
6.
Luo, Jinlan, Shuiqing Hu, Jingrui Liu, et al.. (2024). Cardiac-specific PFKFB3 overexpression prevents diabetic cardiomyopathy via enhancing OPA1 stabilization mediated by K6-linked ubiquitination. Cellular and Molecular Life Sciences. 81(1). 228–228. 10 indexed citations
7.
Luo, Jinlan, et al.. (2024). SGLT2 inhibition, circulating proteins, and insomnia: A mendelian randomization study. Sleep Medicine. 119. 480–487. 3 indexed citations
8.
Luo, Jinlan, et al.. (2024). SGLT2 inhibition, plasma proteins, and heart failure: a proteome-wide Mendelian Randomization and colocalization study. Frontiers in Cardiovascular Medicine. 11. 1371513–1371513. 1 indexed citations
9.
Shi, Lili, et al.. (2024). The protective role of ginsenoside Rg3 in heart diseases and mental disorders. Frontiers in Pharmacology. 15. 1327033–1327033. 11 indexed citations
10.
Shi, Lili, et al.. (2024). SGLT2 inhibition, venous thrombolism, and death due to cardiac causes: a mediation Mendelian randomization study. Frontiers in Cardiovascular Medicine. 11. 1339094–1339094. 1 indexed citations
11.
Shi, Lili, et al.. (2024). APOB and CCL17 as mediators in the protective effect of SGLT2 inhibition against myocardial infarction: Insights from proteome-wide mendelian randomization. European Journal of Pharmacology. 976. 176619–176619. 1 indexed citations
12.
13.
Hu, Shuiqing, Jinlan Luo, Ping Guo, et al.. (2023). Lentinan alleviates diabetic cardiomyopathy by suppressing CAV1/SDHA-regulated mitochondrial dysfunction. Biomedicine & Pharmacotherapy. 167. 115645–115645. 13 indexed citations
14.
Dai, Wenqin, et al.. (2022). Sacubitril/Valsartan for heart failure. Medicine. 101(23). e29149–e29149. 1 indexed citations
15.
Luo, Jinlan, Menglu Fu, Wenhua Li, et al.. (2022). Inulin-type fructans change the gut microbiota and prevent the development of diabetic nephropathy. Pharmacological Research. 183. 106367–106367. 69 indexed citations
16.
Hu, Shuiqing, Jinlan Luo, Menglu Fu, et al.. (2021). Soluble epoxide hydrolase deletion attenuated nicotine-induced arterial stiffness via limiting the loss of SIRT1. American Journal of Physiology-Heart and Circulatory Physiology. 321(2). H353–H368. 4 indexed citations
17.
Luo, Jinlan, Shuiqing Hu, Menglu Fu, et al.. (2021). Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney. Journal of Biological Chemistry. 296. 100667–100667. 17 indexed citations
18.
Fu, Menglu, Yuanyuan Li, Shuiqing Hu, et al.. (2020). The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis. Clinical Cardiology. 43(12). 1478–1493. 60 indexed citations
19.
Fu, Menglu, Jing Yu, Zhihui Chen, et al.. (2020). Epoxyeicosatrienoic acids improve glucose homeostasis by preventing NF-κB-mediated transcription of SGLT2 in renal tubular epithelial cells. Molecular and Cellular Endocrinology. 523. 111149–111149. 17 indexed citations
20.
Luo, Jinlan, et al.. (2016). Colchicine in addition to conventional therapy for pericarditis recurrence. Herz. 41(7). 630–638. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Menglu Fu Breakdown of academic impact, for papers by Yanjun Zhong Breakdown of academic impact, for papers by Afagh Garjani Breakdown of academic impact, for papers by Stanislav Kotlyarov Breakdown of academic impact, for papers by Ping Lv Breakdown of academic impact, for papers by Francesco Palmas Breakdown of academic impact, for papers by Elisabet Rodríguez‐Tomàs Breakdown of academic impact, for papers by Chengxia Kan Breakdown of academic impact, for papers by Weifeng Yao
Rankless by CCL
2026